000132253 001__ 132253
000132253 005__ 20240301161207.0
000132253 0247_ $$2doi$$a10.1016/j.arbres.2023.10.002
000132253 0248_ $$2sideral$$a137373
000132253 037__ $$aART-2024-137373
000132253 041__ $$aeng
000132253 100__ $$ade-Torres, Juan P.
000132253 245__ $$aImpact of Applying the Global Lung Initiative Criteria for Airway Obstruction in GOLD Defined COPD Cohorts: The BODE and CHAIN Experience
000132253 260__ $$c2024
000132253 5060_ $$aAccess copy available to the general public$$fUnrestricted
000132253 5203_ $$aIntroduction
The Global Lung Function Initiative (GLI) has proposed new criteria for airflow limitation (AL) and recommends using these to interpret spirometry. The objective of this study was to explore the impact of the application of the AL GLI criteria in two well characterized GOLD-defined COPD cohorts.
Methods
COPD patients from the BODE (n = 360) and the COPD History Assessment In SpaiN (CHAIN) cohorts (n = 722) were enrolled and followed. Age, gender, pack-years history, BMI, dyspnea, lung function measurements, exercise capacity, BODE index, history of exacerbations and survival were recorded. CT-detected comorbidities were registered in the BODE cohort. The proportion of subjects without AL by GLI criteria was determined in each cohort. The clinical, CT-detected comorbidity, and overall survival of these patients were evaluated.
Results
In total, 18% of the BODE and 15% of the CHAIN cohort did not meet GLI AL criteria. In the BODE and CHAIN cohorts respectively, these patients had a high clinical burden (BODE ≥ 3: 9% and 20%; mMRC ≥ 2: 16% and 45%; exacerbations in the previous year: 31% and 9%; 6MWD < 350 m: 15% and 19%, respectively), and a similar prevalence of CT-diagnosed comorbidities compared with those with GLI AL. They also had a higher rate of long-term mortality – 33% and 22% respectively.
Conclusions
An important proportion of patients from 2 GOLD-defined COPD cohorts did not meet GLI AL criteria at enrolment, although they had a significant burden of disease. Caution must be taken when applying the GLI AL criteria in clinical practice.
000132253 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000132253 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000132253 700__ $$aCasanova, Ciro
000132253 700__ $$0(orcid)0000-0001-9096-2294$$aMarín, José M.$$uUniversidad de Zaragoza
000132253 700__ $$aCabrera, Carlos
000132253 700__ $$aMarín, Marta
000132253 700__ $$aEzponda, Ana
000132253 700__ $$aCosio, Borja G.
000132253 700__ $$aMartínez, Cristina
000132253 700__ $$aSolanes, Ingrid
000132253 700__ $$aFuster, Antonia
000132253 700__ $$aCalle, Myriam
000132253 700__ $$aPeces-Barba, Germán
000132253 700__ $$aGotera, Carolina
000132253 700__ $$aFeu-Collado, Nuria
000132253 700__ $$aMarin, Alicia
000132253 700__ $$aAlcaide, Ana Belén
000132253 700__ $$aSangro, Matilde
000132253 700__ $$aBastarrika, Gorka
000132253 700__ $$aCelli, Bartolome R.
000132253 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000132253 773__ $$g60, 1 (2024), 10-15$$pArch. bronconeumol.$$tArchivos de Bronconeumologia$$x0300-2896
000132253 8564_ $$s859681$$uhttps://zaguan.unizar.es/record/132253/files/texto_completo.pdf$$yVersión publicada
000132253 8564_ $$s2500664$$uhttps://zaguan.unizar.es/record/132253/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000132253 909CO $$ooai:zaguan.unizar.es:132253$$particulos$$pdriver
000132253 951__ $$a2024-03-01-14:53:14
000132253 980__ $$aARTICLE